Clinical TrialJul 9, 2026, 12:11 PM
Serina Therapeutics SER-252 Phase 1b Trial Progresses, Ahead of Schedule
AI Summary
Serina Therapeutics announced the completion of sentinel dosing in Cohort 1 of its Phase 1b registrational clinical trial for SER-252, targeting advanced Parkinson's disease. Following a review of initial safety data, the independent Data Safety Monitoring Committee recommended continued dosing in Cohort 1. The company is now dosing additional patients in the US and Australia and anticipates completing Cohort 1 enrollment and dosing ahead of its previously disclosed guidance of the end of the third quarter of 2026.
Key Highlights
- Sentinel dosing completed in Cohort 1 of Phase 1b trial for SER-252.
- Data Safety Monitoring Committee (DSMC) recommended continued dosing in Cohort 1.
- Dosing of additional patients in Cohort 1 is underway in US and Australia.
- Company expects to complete Cohort 1 enrollment and dosing ahead of Q3 2026 guidance.
- SER-252 is being evaluated for advanced Parkinson's disease.
- The study is a randomized, double-blind, placebo-controlled Phase 1b registrational trial.
Price Impact
More from SER